| Literature DB >> 22700954 |
Stacey B Gabriel1, Joseph G Gleeson2, Tracy J Dixon-Salazar2, Jennifer L Silhavy2, Nitin Udpa3, Jana Schroth2, Stephanie Bielas2, Ashleigh E Schaffer2, Jesus Olvera2, Vineet Bafna3, Maha S Zaki4, Ghada H Abdel-Salam4, Lobna A Mansour5, Laila Selim5, Sawsan Abdel-Hadi5, Naima Marzouki6, Tawfeg Ben-Omran7, Nouriya A Al-Saana8, F Müjgan Sonmez9, Figen Celep10, Matloob Azam11, Kiley J Hill2, Adrienne Collazo2, Ali G Fenstermaker2, Gaia Novarino2, Naiara Akizu2, Kiran V Garimella1, Carrie Sougnez1, Carsten Russ1.
Abstract
The translation of "next-generation" sequencing directly to the clinic is still being assessed but has the potential for genetic diseases to reduce costs, advance accuracy, and point to unsuspected yet treatable conditions. To study its capability in the clinic, we performed whole-exome sequencing in 118 probands with a diagnosis of a pediatric-onset neurodevelopmental disease in which most known causes had been excluded. Twenty-two genes not previously identified as disease-causing were identified in this study (19% of cohort), further establishing exome sequencing as a useful tool for gene discovery. New genes identified included EXOC8 in Joubert syndrome and GFM2 in a patient with microcephaly, simplified gyral pattern, and insulin-dependent diabetes. Exome sequencing uncovered 10 probands (8% of cohort) with mutations in genes known to cause a disease different from the initial diagnosis. Upon further medical evaluation, these mutations were found to account for each proband's disease, leading to a change in diagnosis, some of which led to changes in patient management. Our data provide proof of principle that genomic strategies are useful in clarifying diagnosis in a proportion of patients with neurodevelopmental disorders.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22700954 PMCID: PMC4442637 DOI: 10.1126/scitranslmed.3003544
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956